MedTrace Logo

A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)

NCT01936688 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2022-02-24

No results posted yet for this study

Summary

This study is being conducted to evaluate the efficacy and safety/tolerability of SCH 900222/MK-3222 in a population of participants with moderate-to-severe plaque psoriasis.

Conditions

  • Plaque-type Psoriasis

Interventions

DRUG

MK-3222 200 mg

MK-3222 200 mg administered SC.

DRUG

MK-3222 100 mg

MK-3222 100 mg administered SC.

DRUG

Placebo to MK-3222

Matching placebo to MK-3222 administered SC.

DRUG

Placebo to Etanercept

Matching placebo to etanercept for subcutaneous injection.

DRUG

Etanercept 50 mg

Etanercept 50 mg for subcutaneous injection.

Sponsors & Collaborators

  • Sun Pharmaceutical Industries Limited

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-09-30
Primary Completion
2018-08-31
Completion
2018-08-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01936688 on ClinicalTrials.gov